Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1638 1654 1656
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18175790 | METHODS AND SYSTEMS FOR REAL-TIME, CONTINUOUS PRODUCTION OF NON-VIRAL CARRIER NUCLEIC ACID PARTICLES | Non-Final OA | CORNING INCORPORATED |
| 17913482 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING GAUCHER THERAPEUTICS | Non-Final OA | Generation Bio Co. |
| 18304843 | Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18325332 | Systemic Delivery of Polypeptides | Non-Final OA | The General Hospital Corporation |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | Non-Final OA | Iovance Biotherapeutics Inc. |
| 18311367 | SELF-REGULATING AAV VECTORS FOR SAFE EXPRESSION OF MECP2 IN RETT SYNDROME | Non-Final OA | University of Massachusetts |
| 18015426 | METHOD OF TREATMENT OF CONGENITAL MYASTHENIC SYNDROME USING DOK7 GENE OR POLYPEPTIDE | Non-Final OA | Oxford University Innovation Limited |
| 17843896 | THYMIDINE KINASE GENE | Final Rejection | Genvivo, Inc. |
| 18187884 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME | Non-Final OA | Krystal Biotech, Inc. |
| 18209766 | Conjugated Polymeric Particle and Method of Making Same | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18274649 | Surface Modified Red Blood Cells And Methods Of Generating The Same | Non-Final OA | CITY UNIVERSITY OF HONG KONG |
| 18018552 | UNIVERSAL ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | Non-Final OA | Baylor College of Medicine |
| 18564869 | DENTAL COMPOSITION AND DENTINE CULTURING METHOD | Non-Final OA | AIR WATER INC. |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18472176 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | Non-Final OA | Astellas Institute for Regenerative Medicine |
| 17328966 | METHOD OF TREATMENT | Final Rejection | MONASH UNIVERSITY |
| 18308457 | SYNTHETIC DNA VECTORS AND METHODS OF USE | Non-Final OA | Aldevron, LLC |
| 18340016 | OLIGONUCLEOTIDES TARGETING XBP1 | Non-Final OA | Roche Innovation Center Copenhagen A/S |
| 18329015 | Mannose-Based mRNA Targeted Delivery System and Use Thereof | Non-Final OA | Shenzhen Rhegen Biotechnology Co., Ltd. |
| 18010674 | METHODS OF IDENTIFYING AND CHARACTERIZING ANELLOVIRUSES AND USES THEREOF | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | Final Rejection | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 18101810 | DOUBLE KNOCKOUT (GT/CMAH-KO) PIGS, ORGANS AND TISSUES | Non-Final OA | Indiana University Research and Technology Corp |
| 17996085 | VECTORS FOR THE TREATMENT OF ACID CERAMIDASE DEFICIENCY | Final Rejection | UNIVERSITE D'EVRY VAL D'ESSONNE |
| 17779174 | T-CELL RECEPTOR OF HLA-A11-RESTRICTED HEPATITIS B VIRUS HBC141-151 EPITOPE PEPTIDE, AND APPLICATION THEREOF | Non-Final OA | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES |
| 17573303 | DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9 | Final Rejection | NATIONWIDE CHILDREN'S HOSPITAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy